Zobrazeno 1 - 10
of 28
pro vyhledávání: ''
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
We conducted a prospective cohort study in newly diagnosed systemic light chain (AL) amyloidosis patients (N = 59) to study patient-reported outcomes (PROs) through the first year. The median age was 68 years with 42% female, 8% Black, and 78% lambda
Autor:
Angela Dispenzieri, David Dingli, Betsy LaPlant, Yi Lin, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, Miriam Hobbs, Amie Fonder, Morie A. Gertz, Eli Muchtar, S. Vincent Rajkumar, Nelson Leung, Rahma Warsame, Taxiarchis Kourelis, Shaji Kumar, Martha Q. Lacy, Ronald S. Go, Suzanne R. Hayman, Kristina Laumann, Robert A. Kyle, Wilson I. Gonsalves, Gabriela Perez Burbano, Prashant Kapoor, Francis K. Buadi, Yi L. Hwa
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 1, Pp 1-9 (2020)
Blood Cancer Journal
Blood Cancer Journal
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalido
Autor:
Madhav V. Dhodapkar, Jonathan L. Kaufman, Vikas Gupta, Sagar Lonial, Ajay K. Nooka, Zhengjia Chen, Jiayi Wu, David L. Jaye, Leonard T. Heffner, Craig C. Hofmeister, Subir Goyal, Nisha Joseph, Lawrence H. Boise, Timothy M. Schmidt, Benjamin G. Barwick, Leon Bernal
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-13 (2019)
Blood Cancer Journal
Blood Cancer Journal
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively a
Autor:
Hongyan Wu, Shahrzad Jalali, Tammy Price-Troska, Zhi Zhang Yang, Anne J. Novak, Jose C. Villasboas, Ya Ping Chen, Stephen M. Ansell, Andrew L. Feldman, Hyo Jin Kim
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 10, Pp 1-14 (2019)
Blood Cancer Journal
Blood Cancer Journal
Signal regulatory protein-α (SIRPα) is a key member of the “do-not-eat-me” signaling pathway, but its biological role and clinical relevance in B-cell NHL is relatively unknown. Using biopsy specimens from follicular lymphoma (FL), we identifie
Autor:
Clyde Bailey, Brian A Walker, Sharmilan Thanendrarajan, Erming Tian, Christopher P. Wardell, Faith E. Davies, Gael Sammartino, Jeffrey R. Sawyer, Bart Barlogie, Carolina Schinke, Frits van Rhee, Gareth J. Morgan, Janet L. Lukacs, Maurizio Zangari
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 8, Pp 1-12 (2019)
Blood Cancer Journal
Blood Cancer Journal
Introduction Chromosome instability (CIN) is a driver of copy number aberrations (CNAs) in cancer, and is a major factor leading to tumor heterogeneity and resistance to therapy. By definition, CIN is an increased rate or ongoing acquisition and accu
Autor:
Brandt Jones, Nicola J. Camp, Michael H. Tomasson, Ethan Davis, Karen Curtin, Michael J. Madsen, Cassandra Garner, Justin A. Williams, Martha Glenn
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 3, Pp 1-9 (2019)
Blood Cancer Journal
Blood Cancer Journal
Abnormal serum immunoglobulin (Ig) free light chains (FLC) are established biomarkers of early disease in multiple B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL). Heavy chains have also been shown to be biomarkers in plasm
Autor:
Irbaz Bin Riaz, Morie A. Gertz, Shaji Kumar, M. Hasib Sidiqi, Wilson I. Gonsalves, Martha Q. Lacy, Eli Muchtar, S. Vincent Rajkumar, Angela Dispenzieri, Rahma Warsame, Nelson Leung, Francis K. Buadi, William J. Hogan, Prashant Kapoor, Taxiarchis Kourelis, David Dingli, Mohammed A. Aljama
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 11, Pp 1-8 (2018)
Blood Cancer Journal
Blood Cancer Journal
We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Autor:
Katarina Luptakova, Antonio Palumbo, Shaji Kumar, Tomas Skacel, Paul G. Richardson, Jacob P. Laubach, Dorothy Romanus, Philippe Moreau, Roman Hájek, Meletios A. Dimopoulos, Kenneth C. Anderson, Jesús F. San Miguel
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 11, Pp 1-12 (2018)
Blood Cancer Journal
Blood Cancer Journal
Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or lon
Autor:
Sajitha Sachchithanantham, Kwee Yong, Shameem Mahmood, Stefan Schönland, Ute Hegenbart, Charalampia Kyriakou, Neil Rabin, Christoph Kimmich, Carol J. Whelan, Ashutosh D. Wechalekar, Philip N. Hawkins, Richa Manwani, Tobias Dittrich, Rakesh Popat
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 11, Pp 1-7 (2018)
Blood Cancer Journal
Blood Cancer Journal
High-dose melphalan with autologous stem cell transplantation (ASCT) can induce durable haematological and organ responses in systemic AL amyloidosis (AL). Stringent selection criteria have improved safety of ASCT in AL but most patients are transpla
Autor:
Ellen D. McPhail, Jing Jing Han, Linda Wellik, Thomas E. Witzig, Andrew L. Feldman, Megan M. O’Byrne, Mamta Gupta, Mary Stenson, Matthew J. Maurer
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 11, Pp 1-11 (2018)
Blood Cancer Journal
Blood Cancer Journal
Peripheral T cell lymphomas (PTCL) is a heterogenous group of non-Hodgkin lymphoma and many patients remain refractory to the frontline therapy. Identifying new prognostic markers and treatment is an unmet need in PTCL. We analyzed phospho-STAT3 (pST